Pacific Biosciences at Goldman Sachs

 On Wednesday, 11 June 2025, Pacific Biosciences (NASDAQ:PACB) presented at the Goldman Sachs 46th Annual Global Healthcare Conference, discussing its strategic advancements and challenges. The company highlighted its long-read sequencing technology’s potential and addressed financial performance, emphasizing both growth opportunities and market constraints.

Key Takeaways

• PacBio’s HiFi technology excels in structural variation analysis, aiming for cost parity with short-read sequencing.
• Q1 2024 saw a record $20.1 million in consumable revenue, marking a 26% increase year-over-year.
• The Revio platform can sequence 2,500 genomes annually at $500 per genome, with plans to reduce costs further.
• PacBio is targeting profitability by 2027 through top-line growth, gross margin improvement, and reduced operating expenses.
• The Vega platform’s launch has surpassed expectations, attracting new biopharma and metagenomics customers.

Financial Results

• Q1 2024 consumable revenue reached $20.1 million, a 26% increase from the previous year.
• Revio’s pull-through met expectations, with 200,000 to 250,000 annualized per box.
• Spark chemistry contributed to 90% of Revio consumables sold, enhancing output by 33% and reducing DNA input needs.

Operational Updates

• The Revio platform aims to increase throughput from 2,500 genomes per year to tens of thousands.
• The cost per genome is currently $500, with goals to lower it to a few hundred dollars.
• The Vega platform shipped 28 systems in Q1, with over 50% of customers being new to PacBio.
• A distributor agreement with Haoray in China will expand HLA testing lab access.

Future Outlook

PacBio is focusing on high-throughput long-read sequencing, pausing short-read system development.

• The company aims to capture 5% of the $3 billion whole-genome market.
• Plans include enhancing gross margins through consumable sales and reducing operating expenses by $45 million to $50 million annually.

Q&A Highlights

• Despite capital constraints in the US academic and government sectors, consumable usage remains stable.
• The clinical market, representing 15% of the customer base, shows growth in genetic disease testing and other areas.
• PacBio is proactively managing debt, aiming for a strong financial position to support R&D efforts.

For further details, please refer to the full transcript below.

Full transcript - Goldman Sachs 46th Annual Global Healthcare Conference:

https://www.investing.com/news/transcripts/pacific-biosciences-at-goldman-sachs-sequencing-innovation-and-growth-93CH-4091575

Myriad Genetics at Goldman Sachs Conference

 On Wednesday, 11 June 2025, Myriad Genetics (NASDAQ:MYGN) participated in the Goldman Sachs 46th Annual Global Healthcare Conference. The company’s leadership shared a cautiously optimistic outlook, highlighting strategic growth opportunities while addressing current challenges. Despite slower growth this year, Myriad remains focused on profitability and operational efficiency.

Key Takeaways

• Myriad aims for high single-digit to low double-digit revenue growth, driven by hereditary cancer, molecular profiling, MRD, and prenatal testing.
• The company maintains strong gross margins around 70% and is investing in strategic initiatives like EMR integrations and the Lab of the Future.
• Challenges include EMR integration issues and the impact of UnitedHealthcare’s decision on GeneSight coverage.
• Myriad is leveraging partnerships and technological advancements to enhance its product offerings.

Financial Results

• Gross Margins: Currently around 70%, with plans to maintain and improve.
• OpEx Strategy: Focused on strategic investments in EMR, MRD, and Pathomic, while reducing discretionary spending.
• Revenue Growth: Targeting high single-digit to low double-digit growth long-term.
• ASP Performance: Strong overall, despite headwinds from GeneSight.
• Cost per Test: Improvements expected from Lab of the Future integrations.

Operational Updates

• EMR Integrations: Completed 4,500 integrations last year, addressing challenges in unaffected hereditary cancer with Epic integration.
• GeneSight: Redirected resources to focus on profitability after UnitedHealthcare’s coverage decision.
• Prolaris: Enhanced commercial intensity through new staff and a partnership with Pathomic for AI integration.
• PRECISE MRD: Demonstrated high sensitivity in detecting low-shedding tumors.
• Lab of the Future: Largely complete, expected to drive future margin improvements.
• 
  
• Future Outlook

• Hereditary Cancer: Anticipating mid-to-high single-digit growth, with programs like breast cancer risk assessment.
• Molecular Profiling: Targeting high single-digit to low double-digit growth through Prolaris and comprehensive genomic profiling.
• MRD: Expected double-digit growth, focusing on low-shedding tumors.
• Prenatal Testing: Aiming to maintain or exceed market growth with new assays.
• GeneSight: Growth expectations adjusted to low-to-mid-single-digit.

Q&A Highlights

• MRD Testing: Potential applications beyond recurrence, including therapy de-escalation.
• GeneSight: Challenges in demonstrating health economic value to UnitedHealthcare.
• Investor Communication: Emphasis on conveying the clinical and economic benefits of Myriad’s tests.

In conclusion, Myriad Genetics remains committed to strategic growth and operational efficiency. For a deeper dive into the company’s plans and challenges, refer to the full transcript below.

Full transcript - Goldman Sachs 46th Annual Global Healthcare Conference:

https://www.investing.com/news/transcripts/myriad-genetics-at-goldman-sachs-conference-strategic-growth-amid-challenges-93CH-4091837

Syndax Pharmaceuticals at Goldman Sachs Conference

 On Wednesday, 11 June 2025, Syndax Pharmaceuticals (NASDAQ:SNDX) presented at the Goldman Sachs 46th Annual Global Healthcare Conference, outlining a strategic vision marked by early successes and future growth opportunities. The company highlighted its robust product portfolio, financial stability, and plans for expansion, while acknowledging competitive challenges in the market.

Key Takeaways

• Syndax’s RevuForge and Niktombo drugs show early success in their respective markets, with strong sales and market penetration.
• The company is focused on expanding its indications and maintaining financial stability through profitability.
• Syndax plans to capitalize on its existing products while considering future asset acquisitions.
• The company expects to achieve profitability in the coming years, driven by its current product lineup.

Financial Results

• RevuForge:

- Fourth quarter sales reached $7.7 million, with one-third attributed to stocking.

- First quarter sales surged to $20 million.

- The drug targets KMT2A translocations in acute leukemia, with significant formulary coverage and a growing prescriber base.

• Niktombo:

- Stub quarter sales amounted to $13.6 million.

- The drug, targeting fibrosis and inflammation in chronic GVHD, has a high gross margin.

- Syndax is financially positioned to reach profitability within the next few years.

Operational Updates

• RevuForge:

- Approved for KMT2A translocations, affecting about 10% of AML and ALL cases.

- Clinical trials showed a two-thirds response rate, with many patients proceeding to stem cell transplants.

- The drug is gaining traction among tier 1 and tier 2 institutions, with over 90% formulary coverage.

• Niktombo:

- Launched in January following its approval in August.

- Demonstrates early and durable responses in GVHD patients, with a rapid activation of the transplant center user base.

Future Outlook

• Syndax aims to expand into frontline AML settings with combination trials for unfit populations and phase 3 trials for fit populations.
• The total addressable market for KMT2A and NPM1 is estimated at $2 billion, with a price point of $40,000 per month for approximately 5,000 patients.
• The company anticipates that the combination of RevuForge and Niktombo will drive growth and profitability.

Q&A Highlights

• Syndax’s management expressed confidence in their competitive positioning, noting superior data in the NPM1 pivotal trial compared to competitors.
• They addressed concerns about QTc prolongation, stating it is manageable for physicians.
• The company expects its drugs to be included in NCCN guidelines upon approval.
• While the focus remains on existing products, new acquisitions may be considered to enhance value.

In conclusion, Syndax Pharmaceuticals is poised for growth and profitability, driven by its innovative product offerings and strategic market positioning. For more details, please refer to the full transcript below.

Full transcript - Goldman Sachs 46th Annual Global Healthcare Conference:

https://www.investing.com/news/transcripts/syndax-pharmaceuticals-at-goldman-sachs-conference-strategic-growth-and-profitability-93CH-4092127